Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.64 |
| ▸ | BRD4 | O60885 | 5/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15004563 | 0.86 | SMPD1 (0.67) | SMPD1BRD4GABRA5SMN1; SMN2 | |
| SCHEMBL18896166 | 0.84 | SMPD1 (0.64) | SMPD1BRD4GABRA5SMN1; SMN2 | |
| SCHEMBL630644 | 0.82 | SMPD1 (0.61) | SMPD1GABRA5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10521252 | 0.82 | SMPD1 (0.60) | SMPD1BRD4GABRA5SMN1; SMN2ADORA3 | |
| SCHEMBL630848 | 0.82 | SMPD1 (0.63) | SMPD1NPC1RAB9A | |
| SCHEMBL10519525 | 0.79 | SMPD1 (0.60) | SMPD1GABRA5NPC1RAB9A | |
| SCHEMBL23430651 | 0.79 | POLB (0.50) | SMPD1POLBNPC1RAB9A | |
| SCHEMBL28789794 | 0.78 | SMPD1 (1.00) | SMPD1 | |
| SCHEMBL10157720 | 0.78 | SMPD1 (0.59) | SMPD1GABRA5NPC1RAB9A | |
| SCHEMBL12909761 | 0.77 | SMPD1 (0.57) | SMPD1GABRA5POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | SMPD1 320/4885BRD4 1381/4885GABRA5 1316/4885 |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | SMPD1 320/4885BRD4 1381/4885GABRA5 1316/4885 |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | SMPD1 320/4885BRD4 1381/4885GABRA5 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.